HSTM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HealthStream Inc (HSTM) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has a constructive short-term trend, but it is extended and overbought, while the latest analyst view remains Hold and insiders are actively selling. Since the user wants a direct answer and is unwilling to wait for a better entry, the best call is to hold rather than buy at this price.
HSTM shows a bullish intermediate trend with SMA_5 > SMA_20 > SMA_200 and a positive, expanding MACD histogram (0.159), which supports upward momentum. However, RSI_6 is 84.738, which is clearly overbought and suggests the stock is extended after a strong run. Price at 28.425 is near resistance (R1 28.24 and R2 29.068), leaving limited upside near term and reducing attractiveness for a fresh long-term entry.
["Bullish moving average structure (SMA_5 > SMA_20 > SMA_200)", "MACD histogram is positive and expanding", "Very strong call-heavy options positioning", "Canaccord raised its price target to $24 from $21 after Q1 results", "No recent negative news in the last week"]
["RSI is deeply overbought at 84.738", "Analyst rating remains Hold, not Buy", "Insiders have been selling, with selling up 146.37% over the last month", "Legacy Credentialing and Scheduling churn continues to pressure revenue growth", "Price is near resistance, limiting near-term upside"]
Latest quarter financials were not available because the financial snapshot returned an error, so there is no usable quarter-by-quarter revenue or earnings detail to assess. Based on the analyst note, the latest Q1 update still reflected a continued headwind from churn in legacy Credentialing and Scheduling products, which has been slowing revenue growth for several quarters.
Recent analyst action is mildly positive but still cautious: Canaccord raised its price target to $24 from $21 following Q1 results, but kept a Hold rating. This indicates Wall Street sees some progress, yet overall sentiment remains mixed rather than bullish. Pros: improved target, model updates after Q1, and some operational progress. Cons: Hold rating, lingering churn in legacy products, and no upgrade to a Buy. Overall, the Street view is neutral-to-cautious.
